Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A

Next Previous
X
Search
Trial Profile

An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efmoroctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Registrational
  • Acronyms ASPIRE
  • Sponsors Biogen; Bioverativ

    • Most Recent Events

    • 09 Jul 2019 According to a Swedish Orphan Biovitrum (Sobi) media release, results (n=67) of longitudinal subgroup analysis of the A-LONG and ASPIRE study population were presented at ISTH 2019, the 27th Congress of the International Society on Thrombosis and Haemostasis (Melbourne, Australia, July 2019).
    • 09 Jul 2019 Results (n=67) of longitudinal subgroup analysis of the A-LONG and ASPIRE study population presented in a Swedish Orphan Biovitrum (Sobi) media release.
    • 25 Jun 2019 According to a Swedish Orphan Biovitrum media release, subgroup analysis of the A-LONG and ASPIRE studies will be presented at the 27th Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, 6-10 July 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top